Key result
Cardiac resynchronization therapy in three patients with congenital heart disease and a failing systemic right ventricle was followed by subpulmonic ventricular dysfunction at 3 to 6 months.
Why the study?
Does cardiac resynchronization therapy affect subpulmonic ventricular function in patients with congenital heart disease and a failing systemic right ventricle?
Case Report (n=3)
Does cardiac resynchronization therapy affect subpulmonic ventricular function in patients with congenital heart disease and a failing systemic right ventricle?
Cardiac resynchronization therapy in congenital heart disease patients with a failing systemic right ventricle may lead to delayed subpulmonic ventricular dysfunction, highlighting the need for careful patient selection and registries.
Subpulmonic dysfunction may follow BiV pacing in CHD; hypothesis-generating for indications and lead placement.
BACKGROUND: Cardiac resynchronization therapy is rapidly emerging as an effective strategy for managing ventricular dysfunction and heart failure associated with congenital heart disease. Indications for therapy, optimal lead placement, and late outcomes are however lacking. METHODS: We present three patients, one with Mustard procedure and two with congenitally corrected transposition of great arteries, who developed subpulmonic ventricular dysfunction 3-6 months after biventricular pacing +/- implantable cardioverter defibrillator implantation, despite initial favorable result of resynchronization therapy. Possible factors for adverse outcome are relatively high pacing rate, unfavorable alteration of torsional contraction, and increased atrioventricular valve regurgitation due to suboptimal placement of larger diameter defibrillation leads. RESULTS: Careful evaluation of patients, particularly indications for therapy, need to be rigorous; assessment of hemodynamic response at the time of implant and appropriate programming may improve the effectiveness of cardiac resynchronization therapy (CRT) in this patient population. CONCLUSION: Our case series emphasizes the need for a registry in the absence of randomized controlled trials, in order to identify patients who benefit most from CRT, and, importantly, recognize subgroups that respond poorly.
No takes yet. Share an insight, caveat, or question.
Kiesewetter et al. (2008) conducted a case report in Congenital heart disease with a failing systemic right ventricle (n=3). Cardiac resynchronization therapy was evaluated on Subpulmonic ventricular dysfunction. Cardiac resynchronization therapy in three patients with congenital heart disease and a failing systemic right ventricle was followed by subpulmonic ventricular dysfunction at 3 to 6 months.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: